VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis

British Journal of Dermatology

Volumn 142, Issue 2, 2000, Pages 259-266

  Mommers, J M ^a   Van Rossum, M M ^a   Kooijmans Otero, M E ^a   Parker, G L ^b   Van De Kerkhof, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Vanguard Medica Ltd   (United Kingdom)

Author keywords

Leukotriene; Leukotriene B4; LY 293111; Psoriasis; Relapse; VML 295

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; CLOBETASOL PROPIONATE; KERATIN; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; VIMENTIN;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; INFLAMMATION; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SKIN BIOPSY; TREATMENT FAILURE;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; BENZOIC ACIDS; CLOBETASOL; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE B4; PSORIASIS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 0033998018     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03295.x     Document Type: Article

References (47)

1. 1 van de Kerkhof PCM, Lammers AM. Intraepidermal accumulation of polymorphonuclear leukocytes in chronic stable plaque psoriasis. Dermatologica 1987; 174: 224-7.
2. 2 Cox AJ. Polymorphonuclear leukocytes in psoriasis. In: Psoriasis: Proceedings of the Third International Symposium (Farber EM, Cox AJ, eds). New York: Grune and Stratton, 1981: 233-4.
3. 3 Braun-Falco O, Christophers E. Structural aspects of initial psoriatic lesions. Arch Dermatol Forsch 1974; 251: 95-110.
4. 4 Greaves MW, Camp RD. Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin. Arch Dermatol Res 1988; 280 (Suppl.): 33-41.
5. 5 Schroder JM. Inflammatory mediators and chemoattractants. Clin Dermatol 1995; 13: 137-50.
6. 6 Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568-75.
7. 7 Ford Hutchinson AW, Rackman A. Leukotrienes as mediators of skin inflammation. Br J Dermatol 1983; 109 (Suppl. 25): 26-9.
8. 8 Voorhees JJ. Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses. Arch Dermatol 1983; 119: 541-7.
9. 9 Brain SD, Camp R, Dowd P et al. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J Invest Dermatol 1984; 83: 70-3.
10. 10 Camp R, Jones RR, Brain SD et al. Production of intraepidermal microabscesses by topical application of leukotriene B4. J Invest Dermatol 1984; 82: 202-4.
11. 11 van de Kerkhof PCM, Bauer FW, Maassen de Grood RM. Methotrexate inhibits the leukotriene B4 induced intraepidermal accumulation of polymorphonuclear leukocytes. Br J Dermatol 1985; 113: 251-55.
12. 12 Bauer FW, van de Kerkhof PCM, Maassen de Grood RM. Epidermal hyperproliferation following the induction of microabscesses by leukotriene B4. Br J Dermatol 1986; 114: 409-12.
13. 13 Ford Hutchinson AW, Bray MA, Doig MV et al. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286: 264-5.
14. 14 Lindstrom P, Lerner R, Palmblad J et al. Rapid adhesive responses of endothelial cells and of neutrophils induced by leukotriene B4 are mediated by leucocytic adhesion protein CD18. Scand J Immunol 1990; 31: 737-44.
15. 15 Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323: 645-55.
16. 16 Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell 1990; 62: 3-6.
17. 17 Wollert PS, Menconi MJ, O'Sullivan BP et al. LY255283, a novel leukotriene B4 receptor antagonist, limits activation of neutrophils and prevents acute lung injury induced by endotoxin in pigs. Surgery 1993; 114: 191-8.
18. 18 Allen DL, Hoffman WP, Marder P et al. The effects of LY293111Na, a leukotriene B4 receptor antagonist, on the pulmonary neutrophilia and CD11b expression caused by inhalation of a leukotriene B4 aerosol in rhesus monkeys. J Pharmacol Exp Ther 1996; 277: 341-9.
19. 19 Fretland DJ, Anglin CP, Widomski D et al. Pharmacological activity of the second generation leukotriene B4 receptor antagonist, SC-53228: effects on acute colonic inflammation and hepatic function in rodents. Inflammation 1995; 19: 503-15.
20. 20 Black AK, Camp RD, Mallet AI et al. Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. J Invest Dermatol 1990; 95: 50-4.
21. 21 Kragballe K, Herlin T. Benoxaprofen improves psoriasis. A double-blind study. Arch Dermatol 1983; 119: 548-52.
22. 22 Degreef H, Dockx P, De Doncker P et al. A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor. J Am Acad Dermatol 1990; 22: 751-5.
23. 23 van de Kerkhof PCM, Pelt H, Lucker GP et al. Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. Skin Pharmacol 1996; 9: 307-11.
24. 24 de Jong EMGJ, Vlijmen-Willems IMJJ, Scholte JC et al. Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK886) in psoriasis. Skin Pharmacol 1991; 4: 278-85.
25. 25 Hegemann L, Hatzelmann A, Grewig S et al. Potent antagonism of calmodulin activity in vitro, but lack of antiproliferative effects on keratinocytes by the novel leukotriene biosynthesis inhibitor MK-886. Br J Dermatol 1995; 133: 41-7.
26. 26 Sofia MJ, Floreancig P, Bach N et al. The discovery of LY293111, a novel, potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class. Adv Exp Med Biol 1997; 400A: 381-6.
27. 27 Sawyer JS, Bach NJ, Baker SR et al. Synthetic and structure/ activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist. J Med Chem 1995; 38: 4411-32.
28. 28 Marder P, Sawyer JS, Froelich LL et al. Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist. Biochem Pharmacol 1995; 49: 1683-90.
29. 29 Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL et al. Effect of a leukotriene B4 receptor antagonist LY293111, on allergen induced responses in asthma. Thorax 1996; 51: 1178-84.
30. 30 van Pelt JP, de Jong EMGJ, Erp PEJ et al. The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111). Biochem Pharmacol 1997; 53: 1005-12.
31. 4 receptor antagonist (VML 295) on blood leukocytes, cutaneous inflammation and epidermal proliferation. Skin Pharmacol Appl Skin Physiol 1999 in press.
32. 4 receptor antagonist in the treatment of stable plaque psoriasis. Br J Dermatol 1998; 139: 396-402.
33. 33 Bauer FW, Crombag NHCMN, Boezeman JBM et al. Flow cytometry as a tool for the study of cell kinetics in skin. 2. Cell kinetic data in psoriasis. Br J Dermatol 1981; 104: 271-6.
34. 34 Bauer FW, Crombag NHCMN, de Grood RM et al. Flow cytometry as a tool for the study of cell kinetics in epidermis. Br J Dermatol 1980; 102: 629-39.
35. 35 Glade CP, Erp PEJ, Boezeman JBM et al. Multiparameter flow cytometry as a tool to evaluate antipsoriatic therapy. Br J Dermatol 1997; 137: 367-75.
36. 36 Zettergren JG, Peterson LL, Wuepper KD. Keratolinin: the soluble substrate of epidermal transglutaminase from human and bovine tissue. Proc Natl Acad Sci USA 1984; 81: 238-42.
37. 37 Glade CP, Erp PEJ, Hooijdonk CAEM et al. Topical treatment of psoriatic plaques with 1 alpha, 24 dihydroxyvitamin D3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation. Acta Derm Venereol 1995; 75: 381-5.
38. 38 Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
39. 39 Glade CP, Seegers BAMPA, Meulen EF et al. Multiparameter flow cytometric characterization of epidermal cell suspensions prepared from normal and hyperproliferative human skin using an optimized thermolysin-trypsin protocol. Arch Dermatol Res 1996; 288: 203-10.
40. 40 Ramaekers FC, Puts JJ, Moesker O et al. Antibodies to intermediate filament proteins in the immunohistochemical identification of human tumours: an overview. Histochem J 1983; 15: 691-713.
41. 41 Leigh IM, Pulford KA, Ramaekers FC et al. Psoriasis: maintenance of an intact monolayer basal cell differentiation compartment in spite of hyperproliferation. Br J Dermatol 1985; 113: 53-64.
42. 42 Bauer FW, van Boezeman JBM, Engelen L et al. Monoclonal antibodies for epidermal population analysis. J Invest Dermatol 1986; 87: 72-5.
43. 43 de Waal RM, Semeijn JT, Cornelissen MH et al. Epidermal Langerhans cells contain intermediate-sized filaments of the vimentin type, an immunocytologic study. J Invest Dermatol 1984; 82: 602-4.
44. 44 van Hooijdonk CAEM, Glade CP, van Erp PEJ. TO-PRO-3 iodide: a novel HeNe laser-excitable DNA stain as an alternative for propidium iodide in multiparameter flow cytometry. Cytometry 1994; 17: 185-9.
45. 45 van de Kerkhof PCM, Chang A, van der Walle HB et al. Weekly treatment of psoriasis with a hydrocolloid dressing in combination with triamcinolone acetonide. A controlled comparative study. Acta Derm Venereol 1994; 74: 143-6.
46. 46 Mommers JM, van Erp PEJ, van de Kerkhof PCM. Clobetasol under hydrocolloid occlusion in psoriasis results in a complete block of proliferation and in a rebound of lesions following discontinuation. Dermatology 1999 in press.
47. 47 Glade CP, van Erp PEJ, Werner-Schlenzka H et al. A clinical and flow cytometric model to study remission and relapse in psoriasis. Acta Derm Venereol Suppl. (Stockh) 1998; 78: 180-5.